Redox-sensitive transcriptional regulator (RSTF)

Redox-sensitive transcriptional regulators are a diverse class of proteins that control gene expression in response to fluctuations in the cellular reduction-oxidation (redox) environment (NIH, 2021). These regulators, including Nrf2, NF-kappaB, AP-1, and HIF-1, possess specific molecular sensors—often reactive cysteine residues—that detect reactive oxygen species (ROS) and electrophilic stress (AHA Journals, 2005). Upon activation, they undergo structural changes or nuclear translocation to modulate the transcription of genes involved in antioxidant defense, inflammation, and metabolic adaptation (NIH, 2005). In healthy cells, they maintain redox homeostasis, but their dysregulation is a hallmark of many pathologies, including cancer, neurodegeneration, and chronic inflammatory diseases (NIH, 2018). For instance, Nrf2 activation provides a cytoprotective response against oxidative damage, while chronic NF-kappaB activation drives pro-inflammatory signaling (NIH, 2001). Therapeutic strategies involve either activating these pathways to boost cellular resilience or inhibiting them to suppress disease progression (BenchChem, 2025). Several drugs, such as dimethyl fumarate and omaveloxolone, have been developed to target these regulators, particularly the Nrf2 pathway, for treating conditions like multiple sclerosis and Friedreich's ataxia (MDPI, 2023).

Other names

Redox-sensitive transcription factorRedox-regulated transcription factorRedox-responsive transcriptional regulator

Drugs targeting these regulators typically modulate their activity by reacting with sensitive cysteine residues (e.g., Nrf2 activators), inhibiting upstream degradation (e.g., proteasome inhibitors for NF-kappaB), or blocking co-factor interactions to regulate genes involved in antioxidant defense and inflammation (NIH, 2005; BenchChem, 2025).